We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

LumiQuick Diagnostics

LumiQuick Diagnostics Inc. develops, manufactures and markets high quality point of care tests and other immunoassay ... read more Featured Products: More products

Download Mobile App





LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Image: LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021 (Photo courtesy of LumiQuick Diagnostics, Inc.)
Image: LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021 (Photo courtesy of LumiQuick Diagnostics, Inc.)

LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) highlighted its newly-launched point-of-care lateral flow assays and ELISA kits at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The event provided an opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology and vital research in the field. LumiQuick develops and manufactures extensive product lines that cover point-of-care lateral flow assays, ELISA kits, and other platforms. At AACC 2021, the company highlighted some of its newly-launched products such as the QuickProfile Quantitative Vitamin D rapid test, QuickProfile Zika IgG/IgM antibody rapid test, QuickProfile Chikungunya IgG/IgM antibody rapid test, and Quicknostics Vitamin D ELISA test.

LumiQuick also demonstrated its COVID-19 testing solutions including the QuickProfile 2019-nCoV IgG/IgM Combo Test Card which is an immunochromatography based one step in vitro test. It is designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV, SARS-CoV-2) in human serum, plasma, or whole blood. Rapid 2019-nCoV IgG/IgM Combo Test Card is a supplemental rapid screening tool for symptomatic or asymptomatic carriers of the virus. Also on display was the company’s QuickProfile COVID-19 Antigen Test which is a rapid in vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 virus antigen present in human nasopharynx.

Related Links:
LumiQuick Diagnostics, Inc. 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article
ADLM

Channels

Molecular Diagnostics

view channel
Image: The biomarkers of kidney injury could help lead to the development of safer medications and improve patient outcomes (Photo courtesy of 123RF)

New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury

Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.